Net Loss Per Share - Schedule of Common Stock Securities were Excluded from the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	39,213,210	3,271,771	39,213,210	3,271,771
Stock options issued and outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,417,157	1,015,502	4,417,157	1,015,502
Restricted stock units outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,097,209	73,404	1,097,209	73,404
Change in fair value of GeneFab Option - related party
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,963,344	1,963,344	1,963,344	1,963,344
Warrants to purchase common stock issued in connection with Series A redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	31,735,500	0	31,735,500	0
Performance stock units outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	0	116,567	0	116,567
Contingent earnout common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	0	100,000	0	100,000
Unvested early exercised common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	0	2,954	0	2,954